Mitomycins
- Generic Name
- Mitomycins
- Brand Names
- Jelmyto, Mitosol, Mutamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N4O5
- CAS Number
- 50-07-7
- Unique Ingredient Identifier
- 50SG953SK6
- Background
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of Streptomyces caespitosus. It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discov...
- Indication
For treatment of malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder. Also used as an adjunct to ab externo glaucoma surgery. Mitomycin is also indicated as a pyelocalyceal solution for the treatment of adults with low-grade upper tract urothelial cancer (LG-UTUC).
- Associated Conditions
- Anal Cancer, Bladder Cancer, Breast Cancer, Carcinoma of the Head and Neck, Cervical Cancer, Gastric Adenocarcinoma, Mesothelioma, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Ab externo surgery Glaucoma, Low-grade Upper Tract Urothelial Cancer (LG-UTUC)
- Associated Therapies
- -
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
- Conditions
- Interventions
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT06704191
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation Surgery
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- St. Joseph's Healthcare Hamilton
- Target Recruit Count
- 144
- Registration Number
- NCT06680245
Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of Southampton
- Target Recruit Count
- 176
- Registration Number
- NCT06513065
- Locations
- 🇬🇧
Peritoneal Malignancy Institute Basingstoke - Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom
BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Nottingham University Hospitals NHS Trust
- Target Recruit Count
- 500
- Registration Number
- NCT06462001
- Locations
- 🇬🇧
Nottingham University Hospitals, Nottingham, United Kingdom
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06319820
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇦🇹Medizinische Universitaet Graz, Graz, Austria
🇧🇷Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 50
- Registration Number
- NCT06232005
- Locations
- 🇪🇬
Ahmed Maher, Cairo, القاهرة, Egypt
Precise Neoadjuvant Chemoresection of Low Grade NMIBC
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- University of Bern
- Target Recruit Count
- 28
- Registration Number
- NCT06227065
- Locations
- 🇨🇭
Roland Seiler, Biel, Switzerland
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06211764
- Locations
- 🇺🇸
Low Country Urology Clinics, North Charleston, South Carolina, United States
🇺🇸Houston Metro Urology, Houston, Texas, United States
🇺🇸The Urology Group, Cincinnati, Ohio, United States
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 40
- Registration Number
- NCT05979909
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 33
- Registration Number
- NCT05902533
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Vermont, Burlington, Vermont, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.